用Icotinib治疗的晚期EGFR突变NSCLC患者的血EGFR突变ctDNA动态:第二期多中心试验结果
Yaping Hong1,2, Wu Zhuang1,2, Jinhuo Lai3
1Department of Thoracic Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, No. 420 Fuma Road, Jin'an District, 350014, Fuzhou, China.
Scientific reports
|October 4, 2024
概括
监测EGFR突变非小细胞肺癌 (NSCLC) 患者的循环瘤DNA (ctDNA) 变化,可以预测治疗结果. 治疗后无法检测到的ctDNA表明更长的生存时间,突出了ctDNA.
科学领域:
- 在瘤学瘤学.
- 分子诊断学 分子诊断
- 遗传学 遗传学是一种遗传学.
背景情况:
- 具有EGFR突变 (EGFRm) 的高级非小细胞肺癌 (NSCLC) 受益于向疗法.
- 血表皮生长因子受体突变 (EGFRm) 循环瘤DNA (ctDNA) 显示出预测结果的潜力.
- 关于将ctDNA监测纳入EGFRm NSCLC临床实践的试验数据有限.
研究的目的:
- 调查EGFRmctDNA的动态变化与ICOTINIB治疗的NSCLC患者的临床结果之间的关系.
- 评估基线和四周治疗后ctDNA水平的预测值.
主要方法:
- 这是一项前性多中心试验,涉及98名未接受过治疗的EGFRm发达NSCLC患者.
- 血ctDNA在基线时通过滴滴数字PCR分析,并在开始治疗icotinib后四周进行分析.
- ctDNA动态与无进展生存率 (PFS) 和总生存率 (OS) 的相关性.
主要成果:
- 71.4%的患者具有可检测的基线EGFRmctDNA;45.9%在四周后变得无法检测.
- 治疗后无法检测到ctDNA的患者具有显著更长的PFS和OS.
- 在四周检测到的ctDNA是PFS和OS的独立不良预后因素.
结论:
- 血EGFRmctDNA的动态变化是高级NSCLC治疗疗效的有价值预测因素.
- 在治疗icotinib后达到不可检测的ctDNA水平与有利的临床结果有关.
- ctDNA监测提供了一个有希望的工具,用于指导EGFRm NSCLC管理中的临床决策.
更多相关视频
相关概念视频
02:07Tumor Progression
6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
7.3K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.3K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:38Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K